Drug Trial Radar · NCT05237947
Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Mar 1, 2022
Primary completion
Jan 15, 2027
Study completion Jan 14, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Feb 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 30 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital organs. There are many types of HPV, and some can cause cancer. The World Health Organization recommends a two-dose schedule for adolescents 9-14 and three doses for individuals 15 years old or older. This study examines whether a single dose of HPV vaccine can reduce the frequency with which women between ages 18-30 become infected with HPV.
Conditions
- Human Papillomavirus-Related Cervical Carcinoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedBiological
Given IM
Questionnaire AdministrationOther
Ancillary studies
Recombinant Human Papillomavirus Bivalent VaccineBiological
Given IM
Recombinant Human Papillomavirus Nonavalent VaccineBiological
Given IM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incident persistent human papillomavirus (HPV) 16 or 18 infectionTime frame: 6-month persistence observed during follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
Liberia, Guanacaste Province, Costa Rica
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.